For atrial fibrillation ablation, newer anticoagulant reduces major bleeds

March 20th, 2017 | Posted by admin in Uncategorized

Uninterrupted treatment with dabigatran, a non-vitamin K antagonist oral anticoagulant (NOACs), before, during and after ablation to treat atrial fibrillation significantly reduced the incidence of major bleeding events compared with uninterrupted use of the more established anticoagulant warfarin.
Source: Health Medicine Science Daily

You can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.

Leave a Reply

Your email address will not be published. Required fields are marked *